Next Article in Journal
Isolation, Identification, and Antibacterial Properties of Prodigiosin, a Bioactive Product Produced by a New Serratia marcescens JSSCPM1 Strain: Exploring the Biosynthetic Gene Clusters of Serratia Species for Biological Applications
Next Article in Special Issue
Antimicrobial Stewardship in the Hospital Setting: A Narrative Review
Previous Article in Journal
Resistome and Genome Analysis of an Extensively Drug-Resistant Klebsiella michiganensis KMIB106: Characterization of a Novel KPC Plasmid pB106-1 and a Novel Cointegrate Plasmid pB106-IMP Harboring blaIMP-4 and blaSHV-12
Previous Article in Special Issue
Phenotypic and Genotypic Analysis of Bacterial Pathogens Recovered from Patients Diagnosed with Fever of Unknown Origin in Egypt
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 12
Issue 9
10.3390/antibiotics12091464
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

ICU-Acquired Colonization and Infection Related to Multidrug-Resistant Bacteria in COVID-19 Patients: A Narrative Review

by
Alexandre Gaudet
1,2,†,
Louis Kreitmann
3,4,† and
Saad Nseir
1,5,*
1
Médecine Intensive Réanimation, CHU de Lille, F-59000 Lille, France
2
CNRS, Inserm U1019-UMR9017-CIIL-Centre d’Infection et d’Immunité de Lille, Institut Pasteur de Lille, CHU Lille, Université de Lille, F-59000 Lille, France
3
Centre for Antimicrobial Optimisation, Department of Infectious Disease, Faculty of Medicine, Imperial College London, London W12 0HS, UK
4
Department of Intensive Care Medicine, Imperial College Healthcare NHS Trust, London NW1 5QH, UK
5
Inserm U1285, Université de Lille, CNRS, UMR 8576-UGSF, F-59000 Lille, France
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Antibiotics 2023, 12(9), 1464; https://doi.org/10.3390/antibiotics12091464
Submission received: 4 August 2023 / Revised: 17 September 2023 / Accepted: 18 September 2023 / Published: 20 September 2023
(This article belongs to the Special Issue Antibiotic Resistant Pathogens in Hospital)
Browse Figure
Review Reports Versions Notes

Abstract

:
A large proportion of ICU-acquired infections are related to multidrug-resistant bacteria (MDR). Infections caused by these bacteria are associated with increased mortality, and prolonged duration of mechanical ventilation and ICU stay. The aim of this narrative review is to report on the association between COVID-19 and ICU-acquired colonization or infection related to MDR bacteria. Although a huge amount of literature is available on COVID-19 and MDR bacteria, only a few clinical trials have properly evaluated the association between them using a non-COVID-19 control group and accurate design and statistical methods. The results of these studies suggest that COVID-19 patients are at a similar risk of ICU-acquired MDR colonization compared to non-COVID-19 controls. However, a higher risk of ICU-acquired infection related to MDR bacteria has been reported in several studies, mainly ventilator-associated pneumonia and bloodstream infection. Several potential explanations could be provided for the high incidence of ICU-acquired infections related to MDR. Immunomodulatory treatments, such as corticosteroids, JAK2 inhibitors, and IL-6 receptor antagonist, might play a role in the pathogenesis of these infections. Additionally, a longer stay in the ICU was reported in COVID-19 patients, resulting in higher exposure to well-known risk factors for ICU-acquired MDR infections, such as invasive procedures and antimicrobial treatment. Another possible explanation is the surge during successive COVID-19 waves, with excessive workload and low compliance with preventive measures. Further studies should evaluate the evolution of the incidence of ICU-acquired infections related to MDR bacteria, given the change in COVID-19 patient profiles. A better understanding of the immune status of critically ill COVID-19 patients is required to move to personalized treatment and reduce the risk of ICU-acquired infections. The role of specific preventive measures, such as targeted immunomodulation, should be investigated.

1. Introduction

Patients affected by the most severe form of coronavirus disease 2019 (COVID-19) pneumonia develop acute respiratory distress syndrome (ARDS), characterized by profound and life-threatening hypoxemia. These patients often have a prolonged intensive care unit (ICU) stay and require an extended duration of invasive mechanical ventilation (IMV) [1]. Several studies have shown that critically ill COVID-19 patients present a higher incidence of ICU-acquired infections than non-COVID-19 controls, especially hospital- and ventilator-associated pneumonia (HAP and VAP, respectively) [2] and bloodstream infections (BSI) [3]. They are exposed to broad-spectrum antimicrobials [4], which leads to a sustained antibiotic selection pressure. Consequently, there have been major concerns about the potential impact of the COVID-19 pandemic on the emergence and spread of antimicrobial resistance (AMR) [5].
AMR is an important concern in ICUs, where a significant proportion of secondary infections are attributed to multidrug-resistant (MDR) bacteria [6]. In studies conducted prior to the pandemic, ICU-acquired colonization with MDR bacteria was linked to a longer ICU length-of-stay [7], and ICU-acquired infection with MDR bacteria was associated with a longer duration of IMV [8] and higher mortality [6,9].
Several studies have investigated the burden of AMR among COVID-19 patients (see reviews in [10,11,12,13,14,15]), but most presented important methodological limitations. These include a limited sample size, a retrospective and/or monocentric design, the inclusion of both ICU and non-ICU patients, the absence of a control group of non-COVID-19 patients, and the failure to use appropriate statistical methods to account for important confounding factors.
The main objective of this narrative review is to summarize the evidence from studies that have appropriately investigated the association between COVID-19 and the incidence of ICU-acquired infection and colonization with MDR bacteria. The secondary objectives were to describe the pathophysiology and risk factors for ICU-acquired infection and colonization with MDR bacteria among critically ill COVID-19 patients, to investigate the impact of COVID-19 on the association between ICU-acquired infection and colonization with MDR bacteria and prognostic outcomes, and to review specific preventive measures and future lines of research to limit the emergence and spread of AMR in this population (Figure 1).

2. Methods

We searched the MEDLINE and PubMed databases for articles in English related to bacterial co-infections, secondary infections, bacterial colonization, and/or antibiotic resistance among COVID-19 patients. Further references were added through hand-searching in the relevant literature and verifying references of key papers. We screened the titles and abstracts of papers identified by our search, and assessed the full text of potentially relevant articles. The inclusion of papers in the final manuscript was based on consensus among all three co-authors.
To investigate the primary endpoint (i.e., association between COVID-19 and the incidence of ICU-acquired infection and colonization with MDR bacteria), we selected articles with the following criteria: (1) they provided original data on antibiotic resistance in bacteria isolated from COVID-19 patients; (2) they provided data on ICU-acquired infections and/or colonization with resistant bacteria (i.e., bacteria isolated >48 h following ICU admission); (3) they included a control group of non-COVID-19 patients; and (4) they provided a formal statistical assessment of the relationship between COVID-19 status and any quantitative estimate of antibiotic resistance (e.g., incidence of ICU-acquired infection with multidrug-resistant bacteria, or frequency of resistance to a given antibiotic among bacteria isolated from a given body site), or they provided enough data to perform such assessment.
We assessed the characteristics of the selected studies, including: (1) the study design, setting and sample size (Table 1); (2) whether they presented data on ICU-acquired colonization with resistant bacteria, and if so, whether this had been assessed through systematic measurement (e.g., nasal and/or rectal swabs); (3) whether they presented data on ICU-acquired infection with resistant bacteria, and if so, which type of infection (e.g., VAP, BSI, or all), and whether they also presented data on ICU-acquired infection related to non-resistant bacteria; (4) whether the study included patient-related data, and whether statistical analyses had been adjusted for patient-related factors known to impact the incidence of ICU-acquired infection/colonization with resistant bacteria (Table 2); (5) the main findings regarding the association of COVID-19 with the incidence of ICU-acquired MDR colonization/infection; (6) the main findings regarding the risk factors for ICU-acquired MDR colonization/infection among COVID-19 ICU patients; (7) the main findings regarding the effect of COVID-19 on the association between ICU-acquired MDR colonization/infection and prognostic outcomes (ICU length-of-stay (LOS), duration of IMV, and mortality); and (8) the main methodological limitations (Table 3).
To investigate secondary endpoints, we additionally considered articles related to the pathophysiology and preventive measures of ICU-acquired colonization and infection related to MDR bacteria among critically ill COVID-19 patients.

3. Epidemiology

As presented in Table 1, 24 studies providing estimates of the association between COVID-19 status and ICU-acquired infection/colonization with resistant bacteria fulfilled our inclusion criteria [2,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38].
The majority of these studies presented important methodological limitations, mainly related to a retrospective (n = 21) or single-centered (n = 15) design. Most studies compared COVID-19 ICU patients with a control group of non-COVID-19 ICU patients enrolled before the onset of the pandemic. Most studies (n = 22) focused on ICU-acquired infections, and eight also evaluated ICU-acquired colonization with resistant bacteria. The assessment of antibiotic resistance relied on classical microbiology criteria, but the definitions used to classify bacteria as “difficult-to-treat” or “multidrug-resistant” varied across studies.
Besides the major risk of bias related to the above-mentioned methodological limitations, the most important challenge we faced when attempting to summarize the evidence of the association between COVID-19 and antibiotic resistance in the setting of ICU lay in the variability in the assessment of antibiotic resistance across studies. As presented in Table 2, some studies have estimated the incidence of ICU-acquired infection/colonization with MDR bacteria, while others have documented the incidence of infection/colonization with bacteria of all resistance profiles along with the rates (or frequencies) of resistant strains among isolated bacteria, which made comparison across studies extremely challenging.
Finally, several studies have mostly reported bacteriological data and have failed to provide a clear link between bacteriology (e.g., the result of a blood or tracheal aspirate culture) and patient-related data (infection vs. colonization status, clinical variables, etc.), making any attempt to precisely evaluate the incidence, risk factors, and prognostic impact of ICU-acquired MDR colonization/infection impossible. In line with this, only eight studies have adjusted statistical analyses on patient-level factors known to be associated with the occurrence of ICU-acquired infection/colonization with resistant bacteria.
The main findings of the selected studies on the association between COVID-19 and the incidence of ICU-acquired colonization and infection with MDR bacteria are summarized in Table 3. In the COVID-BMR study, a prospective multicenter study in seven ICUs comparing 367 COVID-19 patients with 680 controls recruited in the same centers before the pandemic, we found that COVID-19 patients had a higher cumulative incidence of ICU-acquired infection with MDR bacteria, both prior to and after adjustment for baseline confounders (adjusted sub-distribution hazard ratio (cHR) 2.50, 95% CI 1.90–3.28) [37]. In this study, the main types of ICU-acquired infections related to MDR bacteria were HAP, VAP, and BSI.
Regarding the incidence of VAP related to MDR bacteria, in the COVAPID study, a retrospective multicenter study (36 ICUs) comparing 568 COVID-19 patients with 1008 controls, the incidence of VAP was significantly higher in COVID-19 patients (36.1%) than in patients with flu (22.2%) or no viral infection (16.5%), but the frequency of MDR strains was lower in COVID-19 patients (23.3%) than in patients with flu (38.4%) and no viral infection (33.8%) [2,39]. Data from this paper can be used to provide estimates of the cumulative incidence of VAP related to MDR bacteria in all three groups (11.8% in COVID-19 patients, 11.6% in flu patients, and 8.6% in patients with no viral infection), which does not suggest that this incidence might be higher among COVID-19 patients (contrarily to the COVID-BMR study [37]). However, in a retrospective multicenter study on 1879 COVID-19 patients and 1879 controls in 94 ICUs, the incidence of a first episode of VAP was higher in COVID-19 patients (adjusted sHR 1.68, 95% CI 1.45–1.96), with a similar frequency of MDR pathogens (except for a lower frequency of MRSA), which would suggest a higher incidence of VAP episodes related to MDR bacteria in the COVID-19 group [24] (in line with the COVID-BMR study [37]). Similarly, in a retrospective monocentric study, COVID-19 patients (n = 90) had a higher incidence of VAP (sHR 1.72, 95% CI 1.14–2.57), including MDR VAP (23% vs. 11%, p = 0.03), than non-COVID-19 controls (n = 82; in line with the COVID-BMR study [37]). Finally, using the REA-REZO surveillance network database, a large retrospective study in France found a higher incidence of VAP [26] among 1687 COVID-19 patients than controls (72,258 non-COVID-19 ICU patients recruited before and during the pandemic), with similar proportions of resistant strains among isolated bacteria, again suggesting that the incidence of ICU-acquired infections related to MDR bacteria might be higher among COVID-19 patients. In conclusion, even if no study has been designed to specifically assess this endpoint, the existing literature suggests that COVID-19 patients may have a higher incidence of VAP related to MDR bacteria than controls, mostly linked to a higher incidence of VAP (related to non-MDR and MDR strains altogether) [13].
Regarding the incidence of BSI related to MDR bacteria, a retrospective monocentric study on 497 COVID-19 patients and 823 controls reported that COVID-19 patients had a higher incidence of BSI related to MDR bacteria [38] (adjusted cause-specific HR (cHR) 2.65, 95% CI 1.25–5.59, in line with the COVID-BMR study [37]). Similarly, a retrospective international study in 53 ICUs found an increased incidence of hospital-acquired BSI related to difficult-to-treat Gram-negative bacteria in COVID-19 (n = 252) vs. controls (n = 577; 19.4% vs. 13%, p = 0.017) [29]. Finally, a large retrospective study in France found a higher incidence of VAP and BSI related to MDR bacteria in COVID-19 patients [30]. In conclusion, the existing literature suggests that COVID-19 patients may have a higher incidence of BSI related to MDR bacteria than controls.
The occurrence of ICU-acquired infections with MDR bacteria is influenced by several factors, but is preceded by colonization in the majority of cases. In the COVID-BMR study, we found that there was no significant difference in the cumulative incidence of ICU-acquired MDR colonization between COVID-19 patients and controls (34.1% vs. 27.9%, adjusted sHR 1.27, 95% CI 0.85–1.88) [37]. These estimates were in line with a monocentric retrospective study where the cumulative incidence of ICU-acquired colonization with MDR bacteria was not statistically different in COVID-19 patients when compared with matched controls (respectively 33% vs. 21% sHR 1.71, 95% CI 0.93–3.12) [16]. Among the studies included in our review, two monocentric retrospective studies reported a similar incidence of ICU-acquired colonization with MDR bacteria in COVID-19 patients vs. controls [18,20]; a monocentric retrospective found a lower incidence of ICU-acquired MDR colonization in COVID-19 vs. control patients (47.4% vs. 81.4%, p = 0.005) [27]; and a multicenter retrospective study found decreased rates of MRSA, VRE, CRE and CRAB in systematic screening samples from COVID-19 in comparison with non-COVID-19 patients [25]. In conclusion, the existing literature suggests that the incidence of ICU-acquired colonization with MDR bacteria is similar or potentially lower in COVID-19 patients vs. controls.
As we discussed in the COVID-BMR study, assessing ICU-acquired MDR colonization and infection separately enables a more precise investigation of the mechanisms leading to the emergence and spread of AMR among COVID-19 ICU patients [37]. As ICU-acquired MDR colonization could be related to the cross-transmission of MDR strains across patients through direct contact with healthcare workers, our findings would suggest that organizational changes triggered by the COVID-19 pandemic—such as the cohorting of patients in dedicated COVID-19 units with strict enforcement of infection prevention and control (IPC) policies, enhanced hand hygiene, use of protective personal equipment (PPE), and efforts to decrease patient contacts—might have had a positive impact on this phenomenon. Second, our findings also suggest that COVID-19 patients might harbor distinct characteristics that make them more susceptible than controls to developing ICU-acquired MDR infections once colonized with a given MDR strain; these factors will be discussed in more detail in paragraph 4 related to pathophysiology.
Regarding the impact of COVID-19 status on the association between ICU-acquired MDR colonization/infection and prognostic outcomes, we have documented, in the COVID-BMR study, that the occurrence of a combined outcome including ICU-acquired colonization and/or infection with MDR bacteria was associated with decreased survival (adjusted cHR 2.61, 95% CI 1.59–4.27) in COVID-19 patients, but not in controls [37]. Interestingly, similar findings were obtained in the study by Buetti et al. (looking at BSI related to DTR Gram-negative bacteria) [29] and in the study by Cogliati Dezza et al. (looking at BSI related to MDR Gram-negative bacteria) [27]. In the study by Piantoni et al., we found that ICU-acquired MDR BSI was associated with increased mortality in the overall cohort (adjusted HR 1.73, 95% CI 1.0–3.0), with no effect of COVID-19 status on this association [38]. Both in COVID-BMR [37] and in the study by Piantoni et al. [38], there was no impact of the occurrence of ICU-acquired colonization and/or infection with MDR bacteria on ICU LOS and on the duration of IMV in the overall cohort, in COVID-19 patients, and in controls.
As presented in Table 3, very few studies have looked into the specific risk factors for ICU-acquired colonization/infection among COVID-19 patients.

4. Pathophysiology

Recent epidemiological data have brought to light a notable increase in the risk of MDR infections among patients hospitalized in ICUs with severe COVID-19. This increased susceptibility to MDR infections can be attributed to several factors. Primarily, the administration of immunomodulatory treatments in the management of critically ill COVID-19 patients in ICUs plays a significant role. These treatments encompass various modalities, including, but not limited to, the widespread use of dexamethasone along with potential adjunctive therapies, such as JAK2 inhibitors and IL-6 receptor antagonists. Thus, in the COVID-BMR study, treatment with steroids was found in 75% of COVID-19 patients, vs. 22% of non-COVID-19 patients [37]. The immunosuppressive effects resulting from these treatments may be contributory factors for the elevated incidence of infections, particularly MDR infections. Interestingly, according to findings from the COVID-BMR study, the increased risk of MDR infection among COVID-19 patients occurs as early as seven days following admission to the ICU [37]. Conversely, other data have identified a heightened risk of VAP occurring around three weeks after admission to the ICU in patients exposed to dexamethasone [40,41]. This apparent discrepancy in the timings of infection onset seems to indicate that other factors are likely to contribute to the higher incidence of MDR infections in critically ill COVID-19 patients.
Consistent data have shed light on the direct involvement of the SARS-CoV-2 virus in triggering post-aggressive immunoparalysis. Comparatively, the inflammatory response to COVID-19 appears to be generally of a more moderate intensity when compared with sepsis, with a prolonged state of immunoparalysis observed among severely ill COVID-19 patients. However, it is crucial to note that immune dysregulation in COVID-19 patients exhibits a heterogeneous pattern. Notably, there is a high incidence of lymphopenia affecting both B and T cell populations, with subsequent impacts on cellular and humoral responses. Furthermore, studies have also indicated the presence of monocyte dysfunction, whose intensity seemingly correlates with disease severity [42,43,44,45]. These immune alterations collectively contribute to the development of an immunodeficient state intrinsically linked to COVID-19, thereby rendering severe COVID-19 patients more susceptible to MDR infections.
Another potential explanation for the higher risk of MDR infections among severely ill COVID-19 patients is the increased likelihood of MDR emergence due to the selection pressure resulting from antibiotic use. Notably, exposure to antibiotics stands as one of the primary risk factors for the development of MDR in ICUs [46]. Furthermore, compelling evidence suggests an elevated frequency of antibiotic administration among severely ill COVID-19 patients, potentially resulting from relaxed antibiotic stewardship during the pandemic. Data from the ISARIC consortium, encompassing nearly 50,000 hospitalized COVID-19 patients, revealed that 37% of patients had been exposed to antibiotics prior to hospital admission. This exposure frequency further increased to over 85% during the initial phase of hospitalization, despite bacterial sampling being conducted in only 17% of patients, with positive bacterial cultures found in less than 3% of the total cohort [4,47]. Consequently, the low occurrence of bacterial coinfections is consistent with the findings from the extensive European study COVID-ICU, which reported a 7% frequency of bacterial coinfections upon admission to the ICU [1]. Similarly, a recent meta-analysis involving over 30,000 patients reported a frequency of confirmed bacterial coinfection during the initial phase of approximately 4%, while the rate of antibiotic administration was 60% [48]. These data highlight the significant disparity between the low occurrence of initial bacterial coinfections in severely ill hospitalized COVID-19 patients and the high frequency of antibiotic exposure.
Furthermore, other hypotheses regarding the characteristics of hospital stays can be postulated to explain the increased risk of MDR infections among patients admitted to the ICU for COVID-19. According to data from the COVID-BMR study, the median length of stay in the ICU for severely ill COVID-19 patients was found to be 15 days, compared with 10 days for patients admitted for other reasons [37]. Additionally, the authors of this study noted increased exposure to invasive medical devices among COVID-19 patients compared with non-COVID-19 patients. This included a higher utilization of extracorporeal membrane oxygenation (ECMO), observed in over 9% of COVID-19 patients compared with 2% of non-COVID-19 patients, as well as arterial catheters, utilized in 97% of COVID-19 patients versus 83% of non-COVID-19 patients. Notably, the study also highlighted an extended duration of exposure to these invasive devices. As compared with non-COVID-19 cases, COVID-19 patients exhibited a median duration of exposure of 16 versus 11 days for central venous catheters, 14 versus 9 days for arterial catheters, and 15 versus 8 days for invasive mechanical ventilation. Consequently, the increased frequency of breaches in the anatomical barrier resulting from prolonged exposure to invasive devices likely contributed to the increased risk of infection among MDR-colonized patients, thereby amplifying the incidence of MDR infections among COVID-19 patients in ICUs.
Lastly, material and organizational factors, such as a surge in patient admissions to ICUs, may also participate in the increased risk of MDR infections among patients admitted for COVID-19. The relationship between the scarcity of ICU beds and the prognosis of hospitalized COVID-19 patients has been well-documented since the initial waves of the pandemic [49,50]. Several factors have been identified to explain this relationship, including a shortage of nursing staff leading to an excessive workload [51], which, in turn, may result in reduced adherence to individual protective measures. Similarly, the inadequate availability of personal protective equipment has also been identified as a contributing factor during the pandemic, potentially heightening the risk of MDR transmission [52].

5. Specific Preventive Measures

Several studies reported a higher incidence of ICU-acquired infections, including those related to MDR bacteria in COVID-19 patients [2,37]. Although this high incidence could be explained by exposure to well-known risk factors, such as invasive procedures and long ICU stays, the role of compliance with preventive measures during the surge was not evaluated. One could argue that general preventive measures should be strictly applied in COVID-19 patients, given the high incidence of ICU-acquired infections in these patients.
To our knowledge, no randomized controlled study has evaluated the efficiency of measures aiming to prevent ICU-acquired infection in COVID-19 patients. Previous studies highlighted a link between microbiota alteration in COVID-19 patients and the severity of inflammation, persistence of ARDS, and mortality [53,54,55,56]. The role of digestive and pulmonary microbiota in the pathogenesis of ICU-acquired infections has also been suggested [57,58]. However, whether the alteration of microbiota results in different effects on ICU-acquired infection in COVID-19 patients, as compared with non-COVID-19 patients is still to be evaluated. In a recent pilot study performed in 17 COVID-19 patients, gut microbiota composition significantly differed between patients with ICU-acquired colonization related to MDR bacteria, compared with those with no MDR bacteria colonization [59]. Further studies are needed to confirm these findings.

6. Future Research

In light of these data, several research paths could be developed in the future to better understand the relationship between COVID-19 and MDR infections.
Firstly, we can question the evolution of the profile of COVID-19 patients. Epidemiological data highlight an increasing proportion of immunocompromised individuals [60] among severely ill COVID-19 patients. Interestingly, recent data suggest a decreased risk of colonization and/or infection with MDR in immunocompromised COVID-19 patients compared with immunocompetent subjects [61]. Thus, the increased proportion of immunocompromised patients among COVID-19 patients may actually decrease the risk of MDR infection in this population.
As previously mentioned, the frequency of immunomodulatory therapies appears to be involved in the increased risk of MDR infection among COVID-19 patients. Immunological investigations highlight significant variability in the degree of pulmonary inflammatory responses among these patients, which seems to correlate with disease severity [62]. These data support the potential benefit of a personalized approach, aiming to initiate immunomodulatory treatments in the most inflammatory patients. Conversely, this strategy could spare immunomodulatory treatments for the least inflammatory patients, for whom the risk–benefit ratio of these therapies may be unfavorable. Studies aiming to explore the potential benefit of such a strategy could thus help to better target the use of immunomodulators in this population.
Finally, other research directions also seem interesting to explore with the goal of reducing the incidence of MDR infections in severely ill COVID-19 patients. These include the use of innovative real-time machine-learning tools incorporating dynamic patient-contact networks to predict colonization and infection with MDR bacteria [63,64]; novel point-of-care molecular diagnostic tests to detect co-infections and decrease the inappropriate use of antibiotics [65]; or the use of specific bundles of care to prevent the incidence of specific ICU-acquired infections [66].

7. Conclusions

Owing to the potential impact of the COVID-19 pandemic on antibiotic stewardship programs and the correct application of IPC measures in hospitals, there have been major concerns about the consequences of COVID-19 on AMR. In this narrative review, we report that critically ill COVID-19 patients, compared with controls, have been shown to present a higher incidence of ICU-acquired infections—particularly VAP and BSI—related to MDR bacteria, despite a similar incidence of ICU-acquired colonization with MDR bacteria. Several pathophysiological factors can explain these findings, including SARS-CoV-2-mediated post-aggressive immunoparalysis, different exposure to antibiotics, steroids, and other immunomodulating agents, a longer ICU LOS and exposure to invasive devices in COVID-19 patients, and organizational constraints triggered by the pandemic. Future lines of research notably include precision medicine approaches to immune modulation in ICU patients.

Author Contributions

Conceptualization, A.G., L.K. and S.N.; methodology, L.K.; writing—original draft preparation, A.G., L.K. and S.N.; writing—review and editing, A.G., L.K. and S.N.; supervision, S.N. All authors have read and agreed to the published version of the manuscript.

Funding

There was no specific funding for this study.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

A.G. has received a clinical research grant from Pfizer. L.K. has received speaking fees and a research scholarship from BioMérieux, and has been employed by Transgene. S.N. has received speaking fees from MSD, Pfizer, Gilead, BioMérieux, Fischer and Paykel, and BioRad.

References

  1. Schmidt, M.; Hajage, D.; Demoule, A.; Pham, T.; Combes, A.; Dres, M.; Lebbah, S.; Kimmoun, A.; Mercat, A.; Beduneau, G.; et al. Clinical Characteristics and Day-90 Outcomes of 4244 Critically Ill Adults with COVID-19: A Prospective Cohort Study. Intensive Care Med. 2021, 47, 60–73. [Google Scholar] [CrossRef]
  2. Rouzé, A.; Martin-Loeches, I.; Povoa, P.; Makris, D.; Artigas, A.; Bouchereau, M.; Lambiotte, F.; Metzelard, M.; Cuchet, P.; Boulle Geronimi, C.; et al. Relationship between SARS-CoV-2 Infection and the Incidence of Ventilator-Associated Lower Respiratory Tract Infections: A European Multicenter Cohort Study. Intensive Care Med. 2021, 47, 188–198. [Google Scholar] [CrossRef] [PubMed]
  3. Buetti, N.; Ruckly, S.; de Montmollin, E.; Reignier, J.; Terzi, N.; Cohen, Y.; Siami, S.; Dupuis, C.; Timsit, J.-F. COVID-19 Increased the Risk of ICU-Acquired Bloodstream Infections: A Case-Cohort Study from the Multicentric OUTCOMEREA Network. Intensive Care Med. 2021, 47, 180–187. [Google Scholar] [CrossRef] [PubMed]
  4. Langford, B.J.; So, M.; Raybardhan, S.; Leung, V.; Soucy, J.-P.R.; Westwood, D.; Daneman, N.; MacFadden, D.R. Antibiotic Prescribing in Patients with COVID-19: Rapid Review and Meta-Analysis. Clin. Microbiol. Infect. 2021, 27, 520–531. [Google Scholar] [CrossRef]
  5. Rawson, T.M.; Ming, D.; Ahmad, R.; Moore, L.S.P.; Holmes, A.H. Antimicrobial Use, Drug-Resistant Infections and COVID-19. Nat. Rev. Microbiol. 2020, 18, 409–410. [Google Scholar] [CrossRef]
  6. Vincent, J.-L.; Sakr, Y.; Singer, M.; Martin-Loeches, I.; Machado, F.R.; Marshall, J.C.; Finfer, S.; Pelosi, P.; Brazzi, L.; Aditianingsih, D.; et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA 2020, 323, 1478–1487. [Google Scholar] [CrossRef]
  7. Barbier, F.; Pommier, C.; Essaied, W.; Garrouste-Orgeas, M.; Schwebel, C.; Ruckly, S.; Dumenil, A.-S.; Lemiale, V.; Mourvillier, B.; Clec’h, C.; et al. Colonization and Infection with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in ICU Patients: What Impact on Outcomes and Carbapenem Exposure? J. Antimicrob. Chemother. 2016, 71, 1088–1097. [Google Scholar] [CrossRef]
  8. Bickenbach, J.; Schöneis, D.; Marx, G.; Marx, N.; Lemmen, S.; Dreher, M. Impact of Multidrug-Resistant Bacteria on Outcome in Patients with Prolonged Weaning. BMC Pulm. Med. 2018, 18, 141. [Google Scholar] [CrossRef]
  9. Barbier, F.; Lisboa, T.; Nseir, S. Understanding Why Resistant Bacteria Are Associated with Higher Mortality in ICU Patients. Intensive Care Med. 2016, 42, 2066–2069. [Google Scholar] [CrossRef]
  10. Hu, S.; You, Y.; Zhang, S.; Tang, J.; Chen, C.; Wen, W.; Wang, C.; Cheng, Y.; Zhou, M.; Feng, Z.; et al. Multidrug-Resistant Infection in COVID-19 Patients: A Meta-Analysis. J. Infect. 2022, 86, P66–P117. [Google Scholar] [CrossRef]
  11. Langford, B.J.; Soucy, J.-P.R.; Leung, V.; So, M.; Kwan, A.T.H.; Portnoff, J.S.; Bertagnolio, S.; Raybardhan, S.; MacFadden, D.; Daneman, N. Antibiotic Resistance Associated with the COVID-19 Pandemic: A Systematic Review and Meta-Analysis. Clin. Microbiol. Infect. 2022, 29, P302–P309. [Google Scholar] [CrossRef] [PubMed]
  12. Kariyawasam, R.M.; Julien, D.A.; Jelinski, D.C.; Larose, S.L.; Rennert-May, E.; Conly, J.M.; Dingle, T.C.; Chen, J.Z.; Tyrrell, G.J.; Ronksley, P.E.; et al. Antimicrobial Resistance (AMR) in COVID-19 Patients: A Systematic Review and Meta-Analysis (November 2019–June 2021). Antimicrob. Resist. Infect. Control 2022, 11, 45. [Google Scholar] [CrossRef] [PubMed]
  13. Boyd, S.; Nseir, S.; Rodriguez, A.; Martin-Loeches, I. Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19 Infection: A Narrative Review. ERJ Open Res. 2022, 8, 00046–02022. [Google Scholar] [CrossRef] [PubMed]
  14. Langford, B.J.; So, M.; Simeonova, M.; Leung, V.; Lo, J.; Kan, T.; Raybardhan, S.; Sapin, M.E.; Mponponsuo, K.; Farrell, A.; et al. Antimicrobial Resistance in Patients with COVID-19: A Systematic Review and Meta-Analysis. Lancet Microbe 2023, 4, e179–e191. [Google Scholar] [CrossRef] [PubMed]
  15. Micheli, G.; Sangiorgi, F.; Catania, F.; Chiuchiarelli, M.; Frondizi, F.; Taddei, E.; Murri, R. The Hidden Cost of COVID-19: Focus on Antimicrobial Resistance in Bloodstream Infections. Microorganisms 2023, 11, 1299. [Google Scholar] [CrossRef]
  16. Bogossian, E.G.; Taccone, F.S.; Izzi, A.; Yin, N.; Garufi, A.; Hublet, S.; Njimi, H.; Ego, A.; Gorham, J.; Byl, B.; et al. The Acquisition of Multidrug-Resistant Bacteria in Patients Admitted to COVID-19 Intensive Care Units: A Monocentric Retrospective Case Control Study. Microorganisms 2020, 8, 1821. [Google Scholar] [CrossRef]
  17. Razazi, K.; Arrestier, R.; Haudebourg, A.F.; Benelli, B.; Carteaux, G.; Decousser, J.-W.; Fourati, S.; Woerther, P.L.; Schlemmer, F.; Charles-Nelson, A.; et al. Risks of Ventilator-Associated Pneumonia and Invasive Pulmonary Aspergillosis in Patients with Viral Acute Respiratory Distress Syndrome Related or Not to Coronavirus 19 Disease. Crit. Care 2020, 24, 699. [Google Scholar] [CrossRef]
  18. Oliva, A.; Ceccarelli, G.; Borrazzo, C.; Ridolfi, M.; D’Ettorre, G.; Alessandri, F.; Ruberto, F.; Pugliese, F.; Raponi, G.M.; Russo, A.; et al. Comparison of Clinical Features and Outcomes in COVID-19 and Influenza Pneumonia Patients Requiring Intensive Care Unit Admission. Infection 2021, 49, 965–975. [Google Scholar] [CrossRef]
  19. Ong, C.C.H.; Farhanah, S.; Linn, K.Z.; Tang, Y.W.; Poon, C.Y.; Lim, A.Y.; Tan, H.R.; Binte Hamed, N.H.; Huan, X.; Puah, S.H.; et al. Nosocomial Infections among COVID-19 Patients: An Analysis of Intensive Care Unit Surveillance Data. Antimicrob. Resist. Infect. Control 2021, 10, 119. [Google Scholar] [CrossRef]
  20. Rouyer, M.; Strazzulla, A.; Youbong, T.; Tarteret, P.; Pitsch, A.; de Pontfarcy, A.; Cassard, B.; Vignier, N.; Pourcine, F.; Jochmans, S.; et al. Ventilator-Associated Pneumonia in COVID-19 Patients: A Retrospective Cohort Study. Antibiotics 2021, 10, 988. [Google Scholar] [CrossRef]
  21. Zuglian, G.; Ripamonti, D.; Tebaldi, A.; Cuntrò, M.; Riva, I.; Farina, C.; Rizzi, M. The Changing Pattern of Bacterial and Fungal Respiratory Isolates in Patients with and without COVID-19 Admitted to Intensive Care Unit. BMC Infect. Dis. 2022, 22, 185. [Google Scholar] [CrossRef] [PubMed]
  22. Bahçe, Y.G.; Acer, Ö.; Özüdoğru, O. Evaluation of Bacterial Agents Isolated from Endotracheal Aspirate Cultures of COVID-19 General Intensive Care Patients and Their Antibiotic Resistance Profiles Compared to Pre-Pandemic Conditions. Microb. Pathog. 2022, 164, 105409. [Google Scholar] [CrossRef] [PubMed]
  23. Sathyakamala, R.; Peace, A.R.; Shanmugam, P. A Comparative Study on Bacterial Co-Infections and Prevalence of Multidrug Resistant Organisms among Patients in COVID and Non-COVID Intensive Care Units. J. Prev. Med. Hyg. 2022, 63, E19–E26. [Google Scholar] [CrossRef] [PubMed]
  24. Vacheron, C.-H.; Lepape, A.; Savey, A.; Machut, A.; Timsit, J.F.; Vanhems, P.; Le, Q.V.; Egbeola, J.; Martin, M.; Maxime, V.; et al. Increased Incidence of Ventilator-Acquired Pneumonia in Coronavirus Disease 2019 Patients: A Multicentric Cohort Study. Crit. Care Med. 2022, 50, 449–459. [Google Scholar] [CrossRef] [PubMed]
  25. Jeon, K.; Jeong, S.; Lee, N.; Park, M.-J.; Song, W.; Kim, H.-S.; Kim, H.S.; Kim, J.-S. Impact of COVID-19 on Antimicrobial Consumption and Spread of Multidrug-Resistance in Bacterial Infections. Antibiotics 2022, 11, 535. [Google Scholar] [CrossRef]
  26. Vacheron, C.-H.; Lepape, A.; Savey, A.; Machut, A.; Timsit, J.F.; Comparot, S.; Courno, G.; Vanhems, P.; Landel, V.; Lavigne, T.; et al. Attributable Mortality of Ventilator-Associated Pneumonia Among Patients with COVID-19. Am. J. Respir. Crit. Care Med. 2022, 206, 161–169. [Google Scholar] [CrossRef]
  27. Cogliati Dezza, F.; Arcari, G.; Alessi, F.; Valeri, S.; Curtolo, A.; Sacco, F.; Ceccarelli, G.; Raponi, G.; Alessandri, F.; Mastroianni, C.M.; et al. Clinical Impact of COVID-19 on Multi-Drug-Resistant Gram-Negative Bacilli Bloodstream Infections in an Intensive Care Unit Setting: Two Pandemics Compared. Antibiotics 2022, 11, 926. [Google Scholar] [CrossRef]
  28. Metan, G.; Demir Çuha, M.; Hazirolan, G.; Telli Dizman, G.; Tanriverdi, E.S.; Otlu, B.; Tas, Z.; Zarakolu, P.; Arik, Z.; Topeli, A.; et al. The Impact of COVID-19 Pandemic on Nosocomial Multidrug-Resistant Bacterial Bloodstream Infections and Antibiotic Consumption in a Tertiary Care Hospital. GMS Hyg. Infect. Control 2022, 17, Doc15. [Google Scholar] [CrossRef]
  29. Buetti, N.; Tabah, A.; Loiodice, A.; Ruckly, S.; Aslan, A.T.; Montrucchio, G.; Cortegiani, A.; Saltoglu, N.; Kayaaslan, B.; Aksoy, F.; et al. Different Epidemiology of Bloodstream Infections in COVID-19 Compared to Non-COVID-19 Critically Ill Patients: A Descriptive Analysis of the Eurobact II Study. Crit. Care 2022, 26, 319. [Google Scholar] [CrossRef]
  30. Lepape, A.; Machut, A.; Bretonnière, C.; Friggeri, A.; Vacheron, C.-H.; Savey, A. REA-REZO network Effect of SARS-CoV-2 Infection and Pandemic Period on Healthcare-Associated Infections Acquired in Intensive Care Units. Clin. Microbiol. Infect. 2022, 29, 530–536. [Google Scholar] [CrossRef]
  31. Kinross, P.; Gagliotti, C.; Merk, H.; Plachouras, D.; Monnet, D.L.; Högberg, L.D.; Group, E.-N.S.; Participants, E.-N.S.G.; Strauss, R.; Mertens, K.; et al. Large Increase in Bloodstream Infections with Carbapenem-Resistant Acinetobacter Species during the First 2 Years of the COVID-19 Pandemic, EU/EEA, 2020 and 2021. Eurosurveillance 2022, 27. [Google Scholar] [CrossRef] [PubMed]
  32. Segala, F.V.; Pafundi, P.C.; Masciocchi, C.; Fiori, B.; Taddei, E.; Antenucci, L.; De Angelis, G.; Guerriero, S.; Pastorino, R.; Damiani, A.; et al. Incidence of Bloodstream Infections Due to Multidrug-Resistant Pathogens in Ordinary Wards and Intensive Care Units before and during the COVID-19 Pandemic: A Real-Life, Retrospective Observational Study. Infection 2023, 51, 1061–1069. [Google Scholar] [CrossRef] [PubMed]
  33. Önal, U.; Tüzemen, Ü.; Kazak, E.; Gençol, N.; Souleiman, E.; İmer, H.; Heper, Y.; Yılmaz, E.; Özakın, C.; Ener, B.; et al. Effects of COVID-19 Pandemic on Healthcare-Associated Infections, Antibiotic Resistance and Consumption Rates in Intensive Care Units. Infez. Med. 2023, 31, 195–203. [Google Scholar] [CrossRef] [PubMed]
  34. Petrakis, V.; Panopoulou, M.; Rafailidis, P.; Lemonakis, N.; Lazaridis, G.; Terzi, I.; Papazoglou, D.; Panagopoulos, P. The Impact of the COVID-19 Pandemic on Antimicrobial Resistance and Management of Bloodstream Infections. Pathogens 2023, 12, 780. [Google Scholar] [CrossRef] [PubMed]
  35. Lee, Y.-M.; Kim, D.Y.; Kim, E.J.; Park, K.-H.; Lee, M.S. Impact of COVID-19 Pandemic on Healthcare-Associated Infections at Intensive Care Units in South Korea: Data from the Korean National Healthcare-Associated Infections Surveillance System (KONIS). J. Hosp. Infect. 2023, 138, 52–59. [Google Scholar] [CrossRef] [PubMed]
  36. Chang, H.-C.; Chang, C.-H.; Tien, K.-L.; Tai, C.-H.; Lin, L.-M.; Lee, T.-F.; Ku, S.-C.; Fang, C.-T.; Chen, Y.-C.; Sheng, W.-H. Impact of Coronavirus Disease 2019 (COVID-19) on Antimicrobial Resistance among Major Pathogens Causing Healthcare-Associated Infection. J. Formos. Med. Assoc. 2023, S0929-6646(23)00254-1. [Google Scholar] [CrossRef]
  37. Kreitmann, L.; Jermoumi, S.; Vasseur, M.; Chabani, M.; Nourry, E.; Richard, J.-C.; Wallet, F.; Garçon, P.; Kachmar, S.; Zerbib, Y.; et al. Relationship between COVID-19 and ICU-Acquired Colonization and Infection Related to Multidrug-Resistant Bacteria: A Prospective Multicenter before-after Study. Intensive Care Med. 2023, 49, 796–807. [Google Scholar] [CrossRef]
  38. Piantoni, A.; Houard, M.; Piga, G.; Zebian, G.; Ruffier des Aimes, S.; Holik, B.; Wallet, F.; Rouzé, A.; Kreitmann, L.; Loiez, C.; et al. Relationship between COVID-19 and ICU-Acquired Bloodstream Infections Related to Multidrug-Resistant Bacteria. Antibiotics 2023, 12, 1105. [Google Scholar] [CrossRef]
  39. Nseir, S.; Martin-Loeches, I.; Povoa, P.; Metzelard, M.; Du Cheyron, D.; Lambiotte, F.; Tamion, F.; Labruyere, M.; Makris, D.; Boulle Geronimi, C.; et al. Relationship between Ventilator-Associated Pneumonia and Mortality in COVID-19 Patients: A Planned Ancillary Analysis of the coVAPid Cohort. Crit. Care 2021, 25, 177. [Google Scholar] [CrossRef]
  40. Saura, O.; Rouzé, A.; Martin-Loeches, I.; Povoa, P.; Kreitmann, L.; Torres, A.; Metzelard, M.; Du Cheyron, D.; Lambiotte, F.; Tamion, F.; et al. Relationship between Corticosteroid Use and Incidence of Ventilator-Associated Pneumonia in COVID-19 Patients: A Retrospective Multicenter Study. Crit. Care 2022, 26, 292. [Google Scholar] [CrossRef]
  41. Lamouche-Wilquin, P.; Souchard, J.; Pere, M.; Raymond, M.; Asfar, P.; Darreau, C.; Reizine, F.; Hourmant, B.; Colin, G.; Rieul, G.; et al. Early Steroids and Ventilator-Associated Pneumonia in COVID-19-Related ARDS. Crit. Care 2022, 26, 233. [Google Scholar] [CrossRef] [PubMed]
  42. Loftus, T.J.; Ungaro, R.; Dirain, M.; Efron, P.A.; Mazer, M.B.; Remy, K.E.; Hotchkiss, R.S.; Zhong, L.; Bacher, R.; Starostik, P.; et al. Overlapping but Disparate Inflammatory and Immunosuppressive Responses to SARS-CoV-2 and Bacterial Sepsis: An Immunological Time Course Analysis. Front. Immunol. 2021, 12, 792448. [Google Scholar] [CrossRef] [PubMed]
  43. Garduno, A.; Martinez, G.S.; Ostadgavahi, A.T.; Kelvin, D.; Cusack, R.; Martin-Loeches, I. Parallel Dysregulated Immune Response in Severe Forms of COVID-19 and Bacterial Sepsis via Single-Cell Transcriptome Sequencing. Biomedicines 2023, 11, 778. [Google Scholar] [CrossRef]
  44. Bonnet, B.; Cosme, J.; Dupuis, C.; Coupez, E.; Adda, M.; Calvet, L.; Fabre, L.; Saint-Sardos, P.; Bereiziat, M.; Vidal, M.; et al. Severe COVID-19 Is Characterized by the Co-Occurrence of Moderate Cytokine Inflammation and Severe Monocyte Dysregulation. EBioMedicine 2021, 73, 103622. [Google Scholar] [CrossRef] [PubMed]
  45. Limmer, A.; Engler, A.; Kattner, S.; Gregorius, J.; Pattberg, K.T.; Schulz, R.; Schwab, J.; Roth, J.; Vogl, T.; Krawczyk, A.; et al. Patients with SARS-CoV-2-Induced Viral Sepsis Simultaneously Show Immune Activation, Impaired Immune Function and a Procoagulatory Disease State. Vaccines 2023, 11, 435. [Google Scholar] [CrossRef]
  46. Rodríguez-Baño, J.; Navarro, M.D.; Romero, L.; Muniain, M.A.; de Cueto, M.; Gálvez, J.; Perea, E.J.; Pascual, A. Risk-Factors for Emerging Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia Coli. Clin. Microbiol. Infect. 2008, 14, 180–183. [Google Scholar] [CrossRef] [PubMed]
  47. Russell, C.D.; Fairfield, C.J.; Drake, T.M.; Turtle, L.; Seaton, R.A.; Wootton, D.G.; Sigfrid, L.; Harrison, E.M.; Docherty, A.B.; de Silva, T.I.; et al. Co-Infections, Secondary Infections, and Antimicrobial Use in Patients Hospitalised with COVID-19 during the First Pandemic Wave from the ISARIC WHO CCP-UK Study: A Multicentre, Prospective Cohort Study. Lancet Microbe 2021, 2, e354–e365. [Google Scholar] [CrossRef]
  48. Calderon, M.; Gysin, G.; Gujjar, A.; McMaster, A.; King, L.; Comandé, D.; Hunter, E.; Payne, B. Bacterial Co-Infection and Antibiotic Stewardship in Patients with COVID-19: A Systematic Review and Meta-Analysis. BMC Infect. Dis. 2023, 23, 14. [Google Scholar] [CrossRef]
  49. Gupta, S.; Hayek, S.S.; Wang, W.; Chan, L.; Mathews, K.S.; Melamed, M.L.; Brenner, S.K.; Leonberg-Yoo, A.; Schenck, E.J.; Radbel, J.; et al. Factors Associated with Death in Critically Ill Patients with Coronavirus Disease 2019 in the US. JAMA Intern. Med. 2020, 180, 1436–1447. [Google Scholar] [CrossRef]
  50. Kadri, S.S.; Sun, J.; Lawandi, A.; Strich, J.R.; Busch, L.M.; Keller, M.; Babiker, A.; Yek, C.; Malik, S.; Krack, J.; et al. Association Between Caseload Surge and COVID-19 Survival in 558 U.S. Hospitals, March to August 2020. Ann. Intern. Med. 2021, 174, 1240–1251. [Google Scholar] [CrossRef]
  51. Lasater, K.B.; Aiken, L.H.; Sloane, D.M.; French, R.; Martin, B.; Reneau, K.; Alexander, M.; McHugh, M.D. Chronic Hospital Nurse Understaffing Meets COVID-19: An Observational Study. BMJ Qual. Saf. 2021, 30, 639–647. [Google Scholar] [CrossRef] [PubMed]
  52. Ranney, M.L.; Griffeth, V.; Jha, A.K. Critical Supply Shortages—The Need for Ventilators and Personal Protective Equipment during the COVID-19 Pandemic. N. Engl. J. Med. 2020, 382, e41. [Google Scholar] [CrossRef] [PubMed]
  53. Dickson, R.P. Lung Microbiota and COVID-19 Severity. Nat. Microbiol. 2021, 6, 1217–1218. [Google Scholar] [CrossRef] [PubMed]
  54. Kullberg, R.F.J.; de Brabander, J.; Boers, L.S.; Biemond, J.J.; Nossent, E.J.; Heunks, L.M.A.; Vlaar, A.P.J.; Bonta, P.I.; van der Poll, T.; Duitman, J.; et al. Lung Microbiota of Critically Ill Patients with COVID-19 Are Associated with Nonresolving Acute Respiratory Distress Syndrome. Am. J. Respir. Crit. Care Med. 2022, 206, 846–856. [Google Scholar] [CrossRef]
  55. Ren, L.; Wang, Y.; Zhong, J.; Li, X.; Xiao, Y.; Li, J.; Yang, J.; Fan, G.; Guo, L.; Shen, Z.; et al. Dynamics of the Upper Respiratory Tract Microbiota and Its Association with Mortality in COVID-19. Am. J. Respir. Crit. Care Med. 2021, 204, 1379–1390. [Google Scholar] [CrossRef] [PubMed]
  56. Trøseid, M.; Holter, J.C.; Holm, K.; Vestad, B.; Sazonova, T.; Granerud, B.K.; Dyrhol-Riise, A.M.; Holten, A.R.; Tonby, K.; Kildal, A.B.; et al. Gut Microbiota Composition during Hospitalization Is Associated with 60-Day Mortality after Severe COVID-19. Crit. Care 2023, 27, 69. [Google Scholar] [CrossRef]
  57. De Pascale, G.; De Maio, F.; Carelli, S.; De Angelis, G.; Cacaci, M.; Montini, L.; Bello, G.; Cutuli, S.L.; Pintaudi, G.; Tanzarella, E.S.; et al. Staphylococcus Aureus Ventilator-Associated Pneumonia in Patients with COVID-19: Clinical Features and Potential Inference with Lung Dysbiosis. Crit. Care 2021, 25, 197. [Google Scholar] [CrossRef]
  58. Tsitsiklis, A.; Zha, B.; Byrne, A.; DeVoe, C.; Levan, S.; Rackaityte, E.; Sunshine, S.; Mick, E.; Ghale, R.; Jauregui, A.; et al. Impaired Immune Signaling and Changes in the Lung Microbiome Precede Secondary Bacterial Pneumonia in COVID-19. Res. Sq. 2021, rs.3.rs-380803. [Google Scholar] [CrossRef]
  59. García-García, J.; Diez-Echave, P.; Yuste, M.E.; Chueca, N.; García, F.; Cabeza-Barrera, J.; Fernández-Varón, E.; Gálvez, J.; Colmenero, M.; Rodríguez-Cabezas, M.E.; et al. Gut Microbiota Composition Can Predict Colonization by Multidrug-Resistant Bacteria in SARS-CoV-2 Patients in Intensive Care Unit: A Pilot Study. Antibiotics 2023, 12, 498. [Google Scholar] [CrossRef]
  60. Singson, J.R.C.; Kirley, P.D.; Pham, H.; Rothrock, G.; Armistead, I.; Meek, J.; Anderson, E.J.; Reeg, L.; Lynfield, R.; Ropp, S.; et al. Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19—COVID-NET, 10 States, March 2020–February 2022. MMWR Morb. Mortal Wkly. Rep. 2022, 71, 878–884. [Google Scholar] [CrossRef]
  61. Kreitmann, L.; Vasseur, M.; Jermoumi, S.; Perche, J.; Richard, J.-C.; Wallet, F.; Chabani, M.; Nourry, E.; Garçon, P.; Zerbib, Y.; et al. Relationship between Immunosuppression and Intensive Care Unit-Acquired Colonization and Infection Related to Multidrug-Resistant Bacteria: A Prospective Multicenter Cohort Study. Intensive Care Med. 2023, 49, 154–165. [Google Scholar] [CrossRef] [PubMed]
  62. Sweet, D.R.; Freeman, M.L.; Zidar, D.A. Immunohematologic Biomarkers in COVID-19: Insights into Pathogenesis, Prognosis, and Prevention. Pathog. Immun. 2023, 8, 17–50. [Google Scholar] [CrossRef] [PubMed]
  63. Price, J.R.; Mookerjee, S.; Dyakova, E.; Myall, A.; Leung, W.; Weiße, A.Y.; Shersing, Y.; Brannigan, E.T.; Galletly, T.; Muir, D. Development and Delivery of a Real-Time Hospital-Onset COVID-19 Surveillance System Using Network Analysis. Clin. Infect. Dis. 2021, 72, 82–89. [Google Scholar] [CrossRef] [PubMed]
  64. Myall, A.; Price, J.R.; Peach, R.L.; Abbas, M.; Mookerjee, S.; Zhu, N.; Ahmad, I.; Ming, D.; Ramzan, F.; Teixeira, D.; et al. Prediction of Hospital-Onset COVID-19 Infections Using Dynamic Networks of Patient Contact: An International Retrospective Cohort Study. Lancet Digit. Health 2022, 4, e573–e583. [Google Scholar] [CrossRef] [PubMed]
  65. Fartoukh, M.; Nseir, S.; Mégarbane, B.; Cohen, Y.; Lafarge, A.; Contou, D.; Thille, A.W.; Galerneau, L.-M.; Reizine, F.; Cour, M.; et al. Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotic Exposure in Severe SARS-CoV-2 Pneumonia: A Multicentre Randomized Controlled Trial. Clin. Microbiol. Infect. 2023, 29, 734–743. [Google Scholar] [CrossRef] [PubMed]
  66. Wolfensberger, A.; Clack, L.; von Felten, S.; Faes Hesse, M.; Saleschus, D.; Meier, M.-T.; Kusejko, K.; Kouyos, R.; Held, L.; Sax, H. Prevention of Non-Ventilator-Associated Hospital-Acquired Pneumonia in Switzerland: A Type 2 Hybrid Effectiveness-Implementation Trial. Lancet Infect. Dis. 2023, 23, 836–846. [Google Scholar] [CrossRef]
Antibiotics 12 01464 g001
Figure 1. ICU-acquired colonization and infection related to multidrug-resistant bacteria in COVID-19 patients: incidence, outcomes, pathophysiology, prevention, and future research axis. BSI, bloodstream infection; ICU-MDR-col/inf, Intensive care unit-acquired multidrug-resistant bacteria colonization or infection; LMV, length of mechanical ventilation; LOS, length of stay; PPE, personal protection equipment; VAP, ventilator-associated pneumonia. α: in COVID-19 vs. non-COVID-19. β: in MDR vs. no MDR.
Figure 1. ICU-acquired colonization and infection related to multidrug-resistant bacteria in COVID-19 patients: incidence, outcomes, pathophysiology, prevention, and future research axis. BSI, bloodstream infection; ICU-MDR-col/inf, Intensive care unit-acquired multidrug-resistant bacteria colonization or infection; LMV, length of mechanical ventilation; LOS, length of stay; PPE, personal protection equipment; VAP, ventilator-associated pneumonia. α: in COVID-19 vs. non-COVID-19. β: in MDR vs. no MDR.
Antibiotics 12 01464 g001
Table 1. Characteristics of the studies included in the review for the assessment of the association between COVID-19 and the incidence of ICU-acquired colonization and infection related to MDR bacteria (primary endpoint).
Table 1. Characteristics of the studies included in the review for the assessment of the association between COVID-19 and the incidence of ICU-acquired colonization and infection related to MDR bacteria (primary endpoint).
StudyYearJournalSettingNb. of CentersDesignSample Size
(Cases vs. Controls)
Bogossian et al. [16]November 2020MicroorganismsBelgium1Retrospective72/72
Razazi et al. [17]December 2020Critical CareFrance1Retrospective90/82
Oliva et al. [18]January 2021InfectionItaly1Retrospective55/19
Rouzé et al. [2]January 2021Intensive Care MedicineEurope36Retrospective568/1008
Ong et al. [19]August 2021Antimicrobial Resistance and Infection ControlSingapore1Prospective71/487
Rouyer et al. [20]August 2021AntibioticsFrance1Retrospective79/188
Zuglian et al. [21]February 2022BMC Infectious DiseasesItaly1Retrospective176/194
Bahçe et al. [22]March 2022Microbial PathogenesisTurkey1Retrospective602/971
Sathyakamala et al. [23]March 2022Journal of Preventive Medicine and HygieneIndia1Retrospective356/292
Vacheron et al. [24]March 2022Critical Care MedicineFrance94Retrospective1879/1879
Jeon et al. [25]April 2022AntibioticsKorea4Retrospective209,107 (total including ICU and non-ICU patients, pre- and per-COVID-19 periods)
Vacheron et al. [26]July 2022American Journal of Respiratory and Critical Care MedicineFrance?Retrospective1687/72,258
Cogliati Dezza et al. [27]July 2022AntibioticsItaly1Retrospective18/28
Metan et al. [28]August 2022GMS Hygiene and Infection ControlTurkey1Retrospective?
Buetti et al. [29]October 2022Critical CareWorld53Retrospective252/577
Lepape et al. [30]October 2022Clinical Microbiology and InfectionFrance110Retrospective4465/63,433
Kinross et al. [31]November 2022EurosurveillanceEurope?Retrospective?
Segala et al. [32]March 2023InfectionItaly1Prospective14,884 (total including cases and controls)
Önal et al. [33]April 2023Le Infezioni in MedicinaTurkey1Retrospective8157 (total including cases and controls)
Petrakis et al. [34]May 2023PathogensGreece1Retrospective823/393
Lee et al. [35]June 2023Journal of Hospital InfectionKorea346Retrospective?
Chang et al. [36]July 2023Journal of the Formosan Medical AssociationTaiwan1Retrospective38,184 ICU patients (total)
Kreitmann et al. [37]July 2023Intensive Care MedicineFrance7Prospective367/680
Piantoni et al. [38]July 2023AntibioticsFrance1Retrospective497/823
ICU, intensive care unit. ? indicates no data in original manuscript.
Table 2. Variables reported in the studies included in the review for the assessment of the primary endpoint.
Table 2. Variables reported in the studies included in the review for the assessment of the primary endpoint.
StudyData on ICU
Patients		Control GroupAssessment of ICU-Acquired MDR
Colonization		Systematic Screening of ICU-Acquired MDR
Colonization		Assessment of ICU-Acquired MDR
Infections		Reporting of ICU-Acquired Non-MDR
Infections		Adjustment for
Confounding Factors
Bogossian et al. [16]YesNon-COVID-19 ICU patients before pandemicYesYesNoNoYes
Razazi et al. [17]YesNon-COVID-19 ICU patients before and during pandemicNoNoYes (VAP)YesYes
Oliva et al. [18]YesFlu patients (before pandemic)YesYesYes (all)YesNo
Rouzé et al. [2]YesICU patients with flu or no viral infection (before and during pandemic)NoNoYes (VA-LTRI, VAP and VAT)YesYes
Ong et al. [19]YesNon-COVID-19 ICU patients during pandemicNoNoYes (all)YesYes
Rouyer et al. [20]YesNon-COVID-19 ICU patients during pandemicYesYesYes (VAP)YesNo
Zuglian et al. [21]YesNon-COVID-19 IUC patients before pandemicNoNoYes (respiratory samples)YesNo
Bahçe et al. [22]YesNon-COVID-19 ICU patients before pandemicNoNoYes (respiratory samples)YesNo
Sathyakamala et al. [23]YesNon-COVID-19 ICU patients during pandemicNoNoYes (all)YesNo
Vacheron et al. [24]YesNon-COVID-19 ICU patients before pandemicNoNoYes (VAP)YesYes
Jeon et al. [25]YesNon-COVID-19 ICU patients before pandemicYes?Yes (all)NoNo
Vacheron et al. [26]YesNon-COVID-19 ICU patients before and during pandemicNoNoYes (VAP)YesNo
Cogliati Dezza et al. [27]YesNon-COVID-19 ICU patients before pandemicYesYesYes (MDR Gram-negative BSI)NoNo
Metan et al. [28]YesNon-COVID-19 ICU patients during pandemicNoNoYes (BSI)NoNo
Buetti et al. [29]YesNon-COVID-19 ICU patients before pandemicNoNoYes (BSI)YesNo
Lepape et al. [30]YesNon-COVID-19 ICU patients during and before pandemicYes?Yes (VAP, HAP, BSI)YesYes
Kinross et al. [31]YesNon-COVID-19 ICU patients during and before pandemicNoNoYes (Acinetobacter spp. BSI)YesNo
Segala et al. [32]YesNon-COVID-19 ICU patients before pandemicYes?Yes (BSI)YesNo
Önal et al. [33]YesNon-COVID-19 ICU patients before and during pandemicNoNoYes (all)YesNo
Petrakis et al. [34]YesNon-COVID-19 ICU patients during pandemicNoNoYes (blood and respiratory samples)YesNo
Lee et al. [35]YesNon-COVID-19 ICU patients before pandemicNoNoYes (all)YesNo
Chang et al. [36]YesNon-COVID-19 ICU patients before pandemicNoNoYes (all)NoNo
Kreitmann et al. [37]YesNon-COVID-19 ICU patients before pandemicYesYesYes (all)NoYes
Piantoni et al. [38]YesNon-COVID-19 ICU patients during same period of follow-upNoNoYes (ICU-acquired MDR BSI)NoYes
BSI, bloodstream infection; HAP, hospital-associated infection; ICU, intensive care unit; MDR, multidrug-resistant; VAP, ventilator-associated pneumonia; VA-LRTI, ventilator-associated lower respiratory tract infection. ? indicates no data in original manuscript.
Table 3. Main findings from the studies included in the review for the assessment of the primary endpoint.
Table 3. Main findings from the studies included in the review for the assessment of the primary endpoint.
StudyIncidence of ICU-Acquired MDR Colonization and InfectionRisk Factors for ICU-Acquired Colonization or Infection among COVID-19 PatientsImpact on OutcomesLimitations
Bogossian et al. [16]No significant association between COVID-19 status and the incidence of ICU-acquired MDR colonization (sHR 1.71 (CI 95% 0.93–3.21)Risk factors for ICU-acquired MDR colonization: vasopressors, antimicrobial therapyLonger duration of ICU and hospital LOS, but no impact on mortality in patients with ICU-acquired MDR colonization (among COVID-19 patients)Small sample size, monocentric study
Razazi et al. [17]COVID-19 patients had higher incidence of VAP (sHR 1.72, 95% CI 1.14–2.57), including MDR VAP (23% vs. 11%, p = 0.03), than non-COVID-19 controlsNo dataNo dataSmall sample size, monocentric study
Oliva et al. [18]No difference in the incidence of ICU-acquired MDR colonization and infection in COVID-19 vs. flu patientsNo dataNo dataSmall sample size, monocentric study
Rouzé et al. [2]Higher incidence of VA-LTRI and VAP in COVID-19 patients vs. patients with flu or no viral infection, with lower rate of MDR bacteria isolated in COVID-19 patients (23.3%) vs. patients with flu (38.4%) and no viral infection (33.8%)No dataNo data
Ong et al. [19]Similar incidence of ICU-acquired infections, including MDR infections in COVID-19 patients vs. controlsNo dataNo dataMonocentric study, small number of events
Rouyer et al. [20]Similar rates of ICU-acquired MDR colonization in COVID-19 vs. controlsNo dataNo dataIncomplete data collection on ICU-acquired MDR infections
Zuglian et al. [21]Similar frequency of MDR P. aeruginosa and Enterobacteriaceae among positive samples in COVID-19 patients and controlsNo dataNo data
Bahçe et al. [22]Rates of antibiotic resistance in K. pneumoniae, A. baumanii, and P. aeruginosa in ETA unchanged for most antibiotics. Increased rate of levofloxacin- and ceftazidime-resistant P. aeruginosa No dataNo dataSmall number of positive ETA samples (lack of power?)
Sathyakamala et al. [23]Similar rates of MDR Gram-negative bacteria among blood, urine, and respiratory samples in COVID-19 patients vs. controlsNo dataNo dataNo formal statistical comparison, incomplete data collection
Vacheron et al. [24]Higher incidence of VAP in COVID-19 patients vs. controls (adjusted sHR 1.68, 95% CI 1.45–1.96) with similar frequency of MDR pathogens (except for a lower frequency of MRSA)No dataNo data
Jeon et al. [25]ICU-acquired MDR colonization: decreased rates of MRSA, VRE, CRE, and CRAB in COVID-19 vs. non-COVID-19 patients. ICU-acquired MDR infection: decreased rates of MRSA, CRAB, and CRPA, and increased rates of VRE and CRE in COVID-19 vs. non-COVID-19 patientsNo dataNo dataRegistry study with no patient-related data
Vacheron et al. [26]Higher incidence of VAP in COVID-19 patients (36.9%) than in both control groups (13.4% and 10.6%), with similar proportions of resistant strainsNo dataHigher mortality related to VAP in the COVID-19 group (but no data on the impact of COVID-19 status on the association between MDR VAP and outcomes)
Cogliati Dezza et al. [27]Lower incidence of ICU-acquired MDR colonization in COVID-19 (47.4%) vs. control patients (81.4%). No significant difference in incidence rate of ICU-acquired BSI with MDR Gram-negative bacteria in COVID-19 vs. control patients.No dataAmong patients with BSI related to MDR Gram-negative bacteria, 30-day mortality higher in COVID-19 patients than in controls (77.8% vs. 21.4%, p < 0.0001)Small sample size, monocentric study
Metan et al. [28]Similar rates of MDR bacteria in BSI in COVID-19 patients and controlsNo dataNo dataSmall sample size, monocentric study, incomplete reporting
Buetti et al. [29]Increased incidence of hospital-acquired BSI related to DTR Gram-negative bacteria in COVID-19 vs. controls (19.4% vs. 13%, p = 0.017)No dataAmong patients with Gram-negative DTR BSIs, 28-day mortality higher in COVID-19 patients than for controls (83.7% vs. 65.3%, p = 0.025)No adjustment of statistical analysis on patient-related confounders
Lepape et al. [30]ICU-acquired MDR colonization: higher incidence in COVID-19 patients vs. controls (6.8% vs. 3.7%, p < 0.001). ICU-acquired MDR infection: higher incidence of VAP and BSI related to MDR bacteria in COVID-19 patients (MRSA, CRE, ESBL, and ceftazidime-resistant P. aeruginosa)No dataNo dataNo clear distinction between colonization and infection in some tables
Kinross et al. [31]Increased incidence of blood cultures positive with Acinetobacter spp., including imipenem-resistant Acinetobacter spp., during COVID-19 periods vs. pre-pandemic periodNo dataNo dataRegistry study, no patient-related data
Segala et al. [32]Similar incidence of ICU-acquired infections in COVID-19 patients vs. controlsNo dataNo data
Önal et al. [33]COVID-19 patients had higher incidence of BSI (but similar rates of other ICU-acquired infections) than controls, with similar rates of MDR bacteriaNo dataNo dataRetrospective, monocentric study
Petrakis et al. [34]Increased rate of resistance to common antibiotics among isolates of K. pneumonia, A. baumanii, and P. aeruginosa in COVID-19 patients vs. controlsNo dataNo dataRetrospective, monocentric study
Lee et al. [35]Increased rate of imipenem-resistant K. pneumonia among ICU-acquired infections in COVID-19 vs. non-COVID-19 patientsNo dataNo dataRegistry study with no patient-related data
Chang et al. [36]No significant change in the incidence of ICU-acquired MDR infections before and after the COVID-19 pandemicNo dataNo dataNo patient data, no assessment of ICU-acquired non-MDR infection
Kreitmann et al. [37] COVID-19 patients had higher incidence of ICU-acquired MDR infections (adjusted sHR 2.50, 95% CI 1.90–3.28), but similar incidence of ICU-acquired MDR colonization (adjusted sHR 1.27, 95% CI 0.85–1.88) vs. controls No data Occurrence of ICU-acquired MDR colonization and/or infection associated with decreased survival (adjusted cHR 2.61, 95% CI 1.59–4.27) in COVID-19 patients, but not in controls. No impact of the occurrence of ICU-acquired MDR colonization and/or infection on ICU LOS and on duration of IMV in the overall cohort, in COVID-19 patients, and in controls No assessment of ICU-acquired non-MDR infection
Piantoni et al. [38]Increased incidence of ICU-acquired BSI related to MDR bacteria, mostly during the period starting after day 15 post-ICU admission (adjusted cHR 4.35, 95% CI 1.58–11.90)No dataICU-acquired MDR BSI associated with increased mortality in overall cohort (adjusted HR 1.73, 95% CI 1.0–3.0, with no effect of COVID-19 status). No association between occurrence of ICU-acquired MDR BSI and ICU LOS and IMV duration in overall cohort, in COVID-19 patients, and in controlsNo assessment of ICU-acquired non-MDR BSI
BSI, bloodstream infection; CRAB, carbapenem-resistant Acinetobacter baumanii; CRE, carbapenem-resistant Enterobacteriaceae; CRPA, ceftazidim-resistant Pseudomonas aeruginosa; ESBL, extended-spectrum beta-lactamase; ETA, endotracheal aspirate; DTR, difficult-to-treat resistance; ICU, intensive care unit; IMV, invasive mechanical ventilation; LOS, length of stay; MDR, multidrug-resistant; MRSA, methicillin-resistant Staphylococcus aureus; VAP, ventilator-associated pneumonia; VA-LRTI, ventilator-associated lower respiratory tract infection; VRE, vancomycin-resistant enterococcus.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Gaudet, A.; Kreitmann, L.; Nseir, S. ICU-Acquired Colonization and Infection Related to Multidrug-Resistant Bacteria in COVID-19 Patients: A Narrative Review. Antibiotics 2023, 12, 1464. https://doi.org/10.3390/antibiotics12091464

AMA Style

Gaudet A, Kreitmann L, Nseir S. ICU-Acquired Colonization and Infection Related to Multidrug-Resistant Bacteria in COVID-19 Patients: A Narrative Review. Antibiotics. 2023; 12(9):1464. https://doi.org/10.3390/antibiotics12091464

Chicago/Turabian Style

Gaudet, Alexandre, Louis Kreitmann, and Saad Nseir. 2023. "ICU-Acquired Colonization and Infection Related to Multidrug-Resistant Bacteria in COVID-19 Patients: A Narrative Review" Antibiotics 12, no. 9: 1464. https://doi.org/10.3390/antibiotics12091464

APA Style

Gaudet, A., Kreitmann, L., & Nseir, S. (2023). ICU-Acquired Colonization and Infection Related to Multidrug-Resistant Bacteria in COVID-19 Patients: A Narrative Review. Antibiotics, 12(9), 1464. https://doi.org/10.3390/antibiotics12091464

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop